Methods
CRSwNP
This was a prospective, randomized, double-blind, placebo-controlled multicenter trial of n=106 CRSwNP patients that was approved by the institutional review boards of the Friedrich-Alexander University Erlangen‐Nürnberg (FAU), Philipps University Marburg, Christian-Albrecht University Kiel (CAU), Charité Berlin, Marienhospital Stuttgart and the University of Regensburg. Patients were recruited between 2005 and 2012 (IRB No. 3201). Molecular biological experiments for determining potential non-invasive biomarkers and analyzing the clinical results were conducted between 2013 and 2020 (IRB Nos. No: 4_20; No: 269_17). All patients consented to the study.